JP2017502014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502014A5 JP2017502014A5 JP2016540554A JP2016540554A JP2017502014A5 JP 2017502014 A5 JP2017502014 A5 JP 2017502014A5 JP 2016540554 A JP2016540554 A JP 2016540554A JP 2016540554 A JP2016540554 A JP 2016540554A JP 2017502014 A5 JP2017502014 A5 JP 2017502014A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer
- delta
- cas number
- therapeutics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919638P | 2013-12-20 | 2013-12-20 | |
| US61/919,638 | 2013-12-20 | ||
| PCT/US2014/071728 WO2015095829A1 (en) | 2013-12-20 | 2014-12-19 | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502014A JP2017502014A (ja) | 2017-01-19 |
| JP2017502014A5 true JP2017502014A5 (https=) | 2018-02-08 |
| JP6727127B2 JP6727127B2 (ja) | 2020-07-29 |
Family
ID=53403792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540554A Active JP6727127B2 (ja) | 2013-12-20 | 2014-12-19 | Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11007183B2 (https=) |
| EP (2) | EP4062917B1 (https=) |
| JP (1) | JP6727127B2 (https=) |
| AU (1) | AU2014368916B2 (https=) |
| ES (2) | ES3059018T3 (https=) |
| WO (1) | WO2015095829A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3613743B1 (en) | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| TWI674262B (zh) | 2011-01-10 | 2019-10-11 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| EP2914296B2 (en) | 2012-11-01 | 2021-09-29 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015116774A1 (en) | 2014-01-29 | 2015-08-06 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| AU2015224576A1 (en) | 2014-03-03 | 2016-09-22 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| WO2015143004A1 (en) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN106333951B (zh) * | 2015-11-24 | 2018-11-02 | 中国科学院大连化学物理研究所 | 一种mTOR激酶抑制剂与MAPK激酶抑制剂的组合物的应用 |
| BR112018012255A2 (pt) * | 2015-12-18 | 2018-12-04 | Ignyta Inc | método para tratar câncer |
| EP3423112A4 (en) * | 2016-02-29 | 2020-02-26 | Madrigal Pharmaceuticals, Inc. | HSP9 INHIBITOR-ACTIVE CONJUGATES |
| RU2754507C2 (ru) | 2016-06-24 | 2021-09-02 | Инфинити Фармасьютикалз, Инк. | Комбинированная терапия |
| AU2018269982B2 (en) * | 2017-05-16 | 2024-06-13 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical BRAF mutations |
| CN110204529A (zh) * | 2018-02-28 | 2019-09-06 | 朱允涛 | 一种氘代的三嗪类化合物的制备方法和用途 |
| CN115135636B (zh) * | 2020-04-29 | 2024-08-23 | 北京泰德制药股份有限公司 | 喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂 |
| CN113667747B (zh) * | 2020-05-14 | 2025-01-24 | 长庚大学 | 治疗口腔癌的方法 |
| KR20250057646A (ko) * | 2023-10-18 | 2025-04-29 | 주식회사 애스톤사이언스 | Kras 면역원성 펩타이드 |
| WO2025110738A1 (ko) * | 2023-11-24 | 2025-05-30 | 주식회사 캐니캐티케어 | 반려동물의 pik3ca 유전자 돌연변이성 종양 검출용 조성물 및 이를 이용한 반려동물의 pik3ca 유전자 돌연변이성 종양 진단방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE220114T1 (de) | 1993-03-19 | 2002-07-15 | Sequenom Inc | Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease |
| US6140053A (en) | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| GB0320059D0 (en) | 2003-08-27 | 2003-10-01 | Solexa Ltd | A method of sequencing |
| LT3305776T (lt) * | 2004-05-14 | 2020-01-10 | Vertex Pharmaceuticals Incorporated | Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais |
| US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
| US20060228721A1 (en) | 2005-04-12 | 2006-10-12 | Leamon John H | Methods for determining sequence variants using ultra-deep sequencing |
| MX2008013578A (es) * | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| WO2010062546A1 (en) | 2008-10-27 | 2010-06-03 | Qiagen Gaithersburg Inc. | Fast results hybrid capture assay on an automated platform |
| CN102665720A (zh) * | 2009-10-12 | 2012-09-12 | 葛兰素史密斯克莱有限责任公司 | 组合 |
| KR20120046018A (ko) | 2010-10-04 | 2012-05-09 | 삼성테크윈 주식회사 | 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출 |
| WO2012068562A2 (en) * | 2010-11-19 | 2012-05-24 | The Regents Of The University Of California | Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas |
| WO2012125848A2 (en) | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| AU2013243429A1 (en) | 2012-04-06 | 2014-10-23 | Merck Patent Gmbh | Methods for treating cancer using PI3K inhibitor and MEK inhibitor |
-
2014
- 2014-12-19 JP JP2016540554A patent/JP6727127B2/ja active Active
- 2014-12-19 US US15/105,839 patent/US11007183B2/en active Active
- 2014-12-19 EP EP22165473.4A patent/EP4062917B1/en active Active
- 2014-12-19 WO PCT/US2014/071728 patent/WO2015095829A1/en not_active Ceased
- 2014-12-19 AU AU2014368916A patent/AU2014368916B2/en active Active
- 2014-12-19 ES ES22165473T patent/ES3059018T3/es active Active
- 2014-12-19 ES ES14871139T patent/ES2918375T3/es active Active
- 2014-12-19 EP EP14871139.3A patent/EP3082957B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502014A5 (https=) | ||
| JP2017502017A5 (https=) | ||
| Janku et al. | Targeting the PI3K pathway in cancer: are we making headway? | |
| JP6727127B2 (ja) | Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置 | |
| Goldman et al. | Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib | |
| JP2017502013A5 (https=) | ||
| RU2016129287A (ru) | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf | |
| JP7405408B2 (ja) | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 | |
| Dickler et al. | Phase II study of taselisib (GDC-0032) in combination with fulvestrant in patients with her2-negative, hormone receptor–positive advanced breast cancer | |
| Neyns et al. | Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma | |
| Prete et al. | Pericytes elicit resistance to vemurafenib and sorafenib therapy in thyroid carcinoma via the TSP-1/TGFβ1 axis | |
| Mao et al. | Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents | |
| Lindauer et al. | Dasatinib | |
| Woo et al. | Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer | |
| Wicki et al. | First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13) | |
| Saiki et al. | MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways | |
| Buchbinder et al. | Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma | |
| JP2022034068A (ja) | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 | |
| Imura et al. | Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma | |
| JP2017502016A5 (https=) | ||
| Leung et al. | Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1/2 inhibitors in cultured breast cancer cell lines | |
| JP2017500320A5 (https=) | ||
| CN105451750A (zh) | 治疗人的实体肿瘤的诺氏梭菌 | |
| Davis et al. | Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models | |
| CN115398010A (zh) | 用于戈沙妥珠单抗疗法的生物标志物 |